Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

KDELR3 Is a Prognostic Biomarker Related to the Immune Infiltration and Chemoresistance of Anticancer Drugs in Uveal Melanoma.

Tytuł:
KDELR3 Is a Prognostic Biomarker Related to the Immune Infiltration and Chemoresistance of Anticancer Drugs in Uveal Melanoma.
Autorzy:
Zhang J; Department of Pharmacy, Linyi Central Hospital, Linyi, Shandong, China.
Zhang J; Department of Traditional Chinese Medicine, Qingdao Eighth People's Hospital, Qingdao, Shandong, China.
Guan J; Department of Traditional Chinese Medicine, Qingdao Eighth People's Hospital, Qingdao, Shandong, China.
Yu L; Department of Traditional Chinese Medicine, Qingdao Eighth People's Hospital, Qingdao, Shandong, China.
Yan S; Department of Cataract, Jinan Aier Eye Hospital, Jinan, Shandong, China.
Źródło:
Disease markers [Dis Markers] 2022 Aug 21; Vol. 2022, pp. 1930185. Date of Electronic Publication: 2022 Aug 21 (Print Publication: 2022).
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 2015- : New York, NY : Hindawi Pub. Corp.
Original Publication: Chichester ; New York : Wiley, c1983-
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Drug Resistance, Neoplasm*/genetics
Adult ; Biomarkers, Tumor/metabolism ; Humans ; Melanoma ; Prognosis ; Uveal Neoplasms
References:
Molecules. 2020 Nov 05;25(21):. (PMID: 33167334)
Int J Biol Sci. 2020 Apr 27;16(12):2014-2028. (PMID: 32549750)
Nat Rev Clin Oncol. 2020 Jun;17(6):341-348. (PMID: 32112054)
Nat Rev Immunol. 2013 Mar;13(3):159-75. (PMID: 23435331)
Prog Retin Eye Res. 2009 Sep;28(5):329-47. (PMID: 19563908)
Lancet. 2001 Jun 2;357(9270):1777-89. (PMID: 11403834)
Cancers (Basel). 2021 Nov 27;13(23):. (PMID: 34885078)
Front Oncol. 2021 Apr 19;11:625452. (PMID: 33954109)
Annu Rev Immunol. 2018 Apr 26;36:193-220. (PMID: 29328787)
Curr Biol. 2006 Nov 21;16(22):2245-51. (PMID: 17113389)
Int J Mol Sci. 2020 Nov 25;21(23):. (PMID: 33255584)
Science. 2016 Apr 22;352(6284):aaf1098. (PMID: 27102489)
Cancers (Basel). 2021 Nov 02;13(21):. (PMID: 34771666)
Biomed Pharmacother. 2020 Dec;132:110859. (PMID: 33120236)
JAMA. 1997 Dec 10;278(22):1804-14. (PMID: 9396641)
Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800)
Cancers (Basel). 2020 Sep 08;12(9):. (PMID: 32911759)
Lancet Neurol. 2012 Jul;11(7):629-42. (PMID: 22710756)
Cell. 2017 Aug 24;170(5):939-955.e24. (PMID: 28803726)
Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
Nat Commun. 2020 Jan 16;11(1):333. (PMID: 31949145)
Virulence. 2018 Jan 1;9(1):522-554. (PMID: 28362216)
Cancer Metastasis Rev. 2017 Mar;36(1):109-140. (PMID: 28229253)
Front Genet. 2021 Apr 09;12:637418. (PMID: 33912215)
Circ Res. 2009 Feb 13;104(3):328-36. (PMID: 19106412)
Nat Rev Immunol. 2017 Nov;17(11):679-690. (PMID: 28757604)
Cancer. 2016 Aug 1;122(15):2299-312. (PMID: 26991400)
Biofactors. 2021 Nov;47(6):914-932. (PMID: 34375483)
Cell Rep. 2015 Mar 10;10(9):1496-1507. (PMID: 25753416)
Nat Rev Dis Primers. 2020 Apr 9;6(1):24. (PMID: 32273508)
Int J Mol Sci. 2021 Sep 16;22(18):. (PMID: 34576180)
Cancer. 2018 Jul 1;124(13):2693-2703. (PMID: 29579316)
J Innate Immun. 2012;4(5-6):454-62. (PMID: 22302072)
Dev Cell. 2022 Feb 28;57(4):512-525.e8. (PMID: 35051356)
J Immunother Cancer. 2018 Feb 12;6(1):13. (PMID: 29433557)
Hum Vaccin Immunother. 2022 May 31;18(3):1903827. (PMID: 33847208)
Curr Oncol Rep. 2020 Jul 28;22(10):104. (PMID: 32725406)
Cells. 2021 Nov 12;10(11):. (PMID: 34831357)
Prog Retin Eye Res. 2020 Mar;75:100800. (PMID: 31563544)
Substance Nomenclature:
0 (Antineoplastic Agents)
0 (Biomarkers, Tumor)
SCR Disease Name:
Uveal melanoma
Entry Date(s):
Date Created: 20220901 Date Completed: 20220907 Latest Revision: 20220907
Update Code:
20240105
PubMed Central ID:
PMC9420630
DOI:
10.1155/2022/1930185
PMID:
36046379
Czasopismo naukowe
Uveal melanoma (UM) is an intraocular malignancy in adults in which approximately 50% of patients develop metastatic diseases and have a poor clinical outcome. Immunotherapies are quickly becoming a need, and recent research has produced some amazing achievements in this area. In the current investigation, an attempt was made to evaluate the prognostic usefulness of KDELR3 in UM, particularly its connection with tumor-infiltrating lymphocytes (TILs). The expression patterns of mRNAs and related clinical data of 80 UM patients were obtained from The Cancer Genome Atlas (TCGA). By using RT-PCR, we were able to investigate whether or not UM cells and D78 cells expressed KDELR3. The Kaplan-Meier approach, as well as univariate and multivariate tests, was utilized in order to investigate the potential predictive significance of KDELR3 expression. The associations between KDELR3 and TILs and immunological checkpoints were analyzed in order to evaluate the effect that KDELR3 may have on UM immunotherapy. On the basis of the differential expression of KDELR3, a distribution of the half-maximal inhibitory concentration (IC50) of various targeted medicines was observed. In this study, we found that the expression of KDELR3 was distinctly increased in most types of tumors. In addition, KDELR3 was highly expressed in UM cells. Moreover, patients with high KDELR3 expression exhibited a shorter overall survival and disease-free survival than those with low KDELR3 expression. Multivariate analyses confirmed that KDELR3 expression was an independent prognostic factor for overall survival and disease-free survival in patients with UM. Furthermore, KDELR3 expression was demonstrated to be positively correlated with macrophage M1, T cell CD8, T cell follicular helper, dendritic cell resting, and T cell CD4 memory activated. Meanwhile, the expression of KDELR3 was related to several immune checkpoints. The IC50 of AP-24534, BHG712, bleomycin, camptothecin, cisplatin, cytarabine, GSK1070916, and tipifarnib was higher in the KDELR3 high-expression group. In conclusion, KDELR3 may be applied as a potential diagnostic and prognostic biomarker for UM patients.
Competing Interests: The authors declare that they have no competing interests.
(Copyright © 2022 Jingnan Zhang et al.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies